Drugs / Survivin-targeted DC Cell Injection
Survivin-targeted DC Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07715097 | Sep 2026 → Sep 2028 expected | glioblastoma | Beijing Tricision Biotherapeutics Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Survivin-targeted DC Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07715097 ↗ |
| Modality | Cell therapy | “Survivin-targeted DC cell injection regimen” NCT07715097 ↗ |
| Route | Intravenous | “Administration routes include intradermal and intravenous injection.” NCT07715097 ↗ |